Quantum BioPharma’s Huge Biopharma Australia has signed an agreement with a contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS. The oral formulation of Lucid-MS will serve as the drug product for the Company’s Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost with multiple sclerosis. To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Reports Promising PET Tracer Results for MS
- Quantum BioPharma announces results from study on PET tracer
- Quantum BioPharma Reports Strong Q2 2025 with Key Developments
- Quantum Group reports Q2 operating expenses $4.9M vs $3.4M last quarter
- Quantum Biopharma Reports Increased Liabilities in Latest Financial Statement